And also, "adefovir dipovixil".

Adefovir dipovixil (formerly bis-POM PMEA) is Gilead Science's experimental anti-HIV drug. It has a very long half-life within the body, which means that it only needs to be taken once a day. It shows broad-spectrum antiviral activity against hepatitis B and herpes viruses, especially CMV and Epstein Barr, in addition to its activity against HIV. Adefovir and PMPA, new derivatives now entering clinical trials, are nucleotide analogs, which are similar to nucleoside analogs but do not need to undergo as much processing within cells to become active. Both classes of drugs attack reverse transcriptors, so HIV resistance can cover both drug classes at once. Both drugs reduced viral load by 70 percent at differing levels, but viral load rebounded when treatment was stopped. Side effects occurred more frequently at higher dosages. The fear in using these drugs for HIV treatment is that patients risk developing breakthrough CMV infections which are cross-resistant to adefovir and other CMV medications. It may be best to limit adefovir to those needing it for CMV prophylaxis.